ASTH vs ZTS: fair value comparison
Astrana Health, Inc. and Zoetis Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ZTS currently sits closer to the top of our discount ranking. ZTS carries the stronger quality grade.
| ASTH | ZTS | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $35.91 | $77.34 |
| 12-month range | $22.32–$49.81 | $77.10–$152.88 |
| Sector rank | #7 of 113 Healthcare | #5 of 113 Healthcare |
| Quality grade | D | C |
| Momentum grade | — | B |
| Leverage | High | Moderate |
| Margin trend | — | Expanding |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: ASTH fair value analysis · ZTS fair value analysis